Synopsis
ゴジラvsビオランテ
“The winner of this battle would be the most enormous enemy against human beings.”
After the previous Godzilla attack, a miniature arms race ensues to collect his cells. Concerned over Godzilla's possible return, the Japanese government uses the cells to create a new bio-weapon, ANEB (Anti-Nuclear Energy Bacteria). They seeks the aid of geneticist Genshiro Shiragami, who's experiments result in a new mutation.
Other Titles From Toho Pictures
Action + Science Fiction in Japan
324 Japan titles in our catalog blend the Action and Science Fiction genres. Below: the top-rated of them (excluding Godzilla vs. Biollante itself).
The 1988–1990 Japan Window
Godzilla vs. Biollante holds position #34 of 110 Japan films in the 1988–1990 window, below highlighted by audience rating.
The 1980s Japan Landscape
1989 was the decade’s peak output year for Japan — 44 titles released, including Godzilla vs. Biollante. Bars below show how the 1980s stacked up year by year (280 total).
Budget & Box Office Efficiency
At a 1h 45m runtime, production spent $48K per minute on screen and earned $67K per minute back.
Position in Catalog
Released alongside 43 other Japan films in 1989.
The 803rd Japan title from Japan we index (earliest catalogued entry: 1899).
Our Japan catalog contains 4,579 titles in total (2,908 films).
Audience Engagement
189 audience reviews — more than 85% of Japan films in our index.
Review volume (85th percentile) outruns trending popularity (62th) — a durable title with sustained audience attention.
Reception Benchmarks
Ranked #1,547 of 4,579 Japan films indexed here (66th percentile by TMDB audience score).
Rating is +0.4 points above the Japan average of 6.9/10.
Among Japan Action productions specifically: #661 of 1,714 (top 39%).
Production Details
| Primary Country | Japan |
|---|---|
| Original Language | Japanese |
| Spoken Languages | English, Japanese |
| Production Companies | Toho Pictures |
| Runtime | 1h 45m |
| Release Date | December 16, 1989 |
| IMDb | tt0097444 |



















